Translational Research

31. Electroporation As A Method For Genetic Modification 11/9/2024

    In this clip, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics explain why electroporation has a higher gene editing efficiency than that of the viral vector method.

32. Base Editing's Advantages When Combined With Non-Viral Delivery Methods 11/9/2024

    In this segment, Paul Kopesky of Beam Therapeutics shares information on the advantages base editing has over other gene editing approaches when combined with non-viral delivery methods as well as how Beam addresses the challenge of achieving therapeutic levels of editing and target tissues using non-viral delivery systems.

33. Real-Time Monitoring And Automated Sampling For Enhanced Efficiency 3/17/2025

    Integrating real-time, in-line monitoring with automated sampling in bioprocessing enhances efficiency and precision. Discover how advanced spectroscopy provides non-destructive insights to optimize cell growth and productivity.

34. Can Kinetics Provide Detailed Information About Binding Interactions? 2/17/2022

    See the potential value kinetics brings to deepen the understanding of biological processes.

35. NK Cells' Role In Non-Viral Approaches To Genetic Engineering 11/9/2024

    Here, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics each share their take on the primary challenge to modifying NK cells.